sinc
merscov
caus
case
death
countri
saudi
arabia
affect
countri
case
local
death
rate
current
serolog
assay
microneutr
mn
plaqu
reduct
neutral
immunofluoresc
protein
microarray
pseudoparticl
neutral
assay
reli
handl
live
merscov
high
contain
laboratori
need
expens
special
equip
reagent
highli
train
personnel
repres
technic
hurdl
laboratori
resourcelimit
merscov
endem
countri
develop
compar
evalu
three
differ
indirect
elisa
base
merscov
nucleocapsid
protein
n
spike
ectodomain
amino
acid
subunit
amino
acid
compar
mn
assay
develop
elisa
evalu
use
larg
number
confirm
seroposit
sampl
seroneg
sampl
merscov
human
serum
sampl
rselisa
maintain
high
sensit
specif
across
wider
rang
od
valu
compar
rnelisa
moreov
rsbase
elisa
show
better
agreement
correl
mn
assay
contrast
rnelisa
collect
data
demonstr
rselisa
reliabl
rnelisa
repres
suitabl
choic
seroepidemiolog
test
surveil
merscov
endem
region
sever
merscov
serolog
assay
develop
http
doi
middl
east
respiratori
syndrom
coronaviru
merscov
novel
zoonot
lineag
c
betacoronaviru
first
identifi
saudi
arabia
zaki
et
al
viru
caus
diseas
rang
asymptomat
infect
mild
sever
respiratori
diseas
usual
follow
multiorgan
failur
death
elderli
individu
comorbid
april
merscov
caus
laboratoryconfirm
case
countri
fatal
rate
death
index
mer
patient
nonendem
region
travel
histori
middl
east
de
groot
et
al
far
saudi
arabia
report
case
total
death
local
death
rate
current
evid
suggest
mer
zoonot
infect
like
dromedari
camel
alagaili
et
al
azhar
et
al
usual
follow
limit
humantohuman
spread
outbreak
healthcar
household
set
one
larg
crosssect
studi
saudi
arabia
suggest
low
seropreval
merscov
gener
popul
compar
highrisk
group
shepherd
slaughterhous
worker
respect
util
epidemiolog
surveil
studi
especi
endem
region
serolog
detect
merscov
antibodi
ab
patient
base
screen
indirect
elisa
use
merscov
nucleocapsid
n
protein
confirm
immunofluoresc
assay
ifa
merscov
infect
cell
andor
microneutr
mn
assay
alabdallat
et
al
indirect
elisa
base
recombin
mersspik
ectodomain
protein
amino
acid
recent
includ
algorithm
trivedi
et
al
group
also
use
sever
assay
protein
microarray
ifa
stain
base
cell
express
recombin
full
length
protein
plaqu
reduct
neutral
test
prnt
merscov
pseudoparticl
neutral
ppnt
assay
indirect
elisa
base
recombin
protein
perera
et
al
reusken
et
al
zhao
et
al
hemida
et
al
meyer
et
al
fukuma
et
al
grehan
et
al
et
al
muth
et
al
park
et
al
chan
et
al
recent
sbase
competit
elisa
celisa
base
neutral
monoclon
ab
mab
develop
shown
correl
well
neutral
assay
high
sensit
specif
fukushi
et
al
aforement
serolog
assay
associ
sever
drawback
limit
especi
endem
area
exampl
gold
standard
neutral
method
mn
prnt
requir
high
contain
laboratori
limit
avail
endem
region
furthermor
protein
microarray
celisa
ifa
ppnt
requir
expens
special
equip
reagent
highli
train
technic
staff
repres
technic
hurdl
laboratori
middl
east
hand
indirect
elisa
simpl
rapid
cheap
requir
high
contain
facil
make
suitabl
choic
especi
resourcelimit
region
howev
limit
number
report
test
human
clinic
sampl
mainli
due
lack
wellcharacter
human
sera
therefor
goal
studi
develop
valid
compar
hous
develop
indirect
elisa
detect
merscov
ab
base
recombin
n
protein
use
larg
number
well
character
human
serum
sampl
african
green
monkey
kidneyderiv
vero
cell
atcc
grown
maintain
previous
describ
alamri
et
al
human
merscov
isol
alamri
et
al
passag
titrat
tissu
cultur
infect
dose
tcid
assay
vero
cell
previous
describ
coleman
frieman
total
archiv
serum
sampl
obtain
healthi
blood
donor
confirm
neg
merscov
test
live
viru
mn
assay
use
determin
preliminari
cutoff
valu
develop
indirect
elisa
posit
control
serum
sampl
collect
confirm
mer
patient
previou
studi
azhar
et
al
second
set
specimen
includ
serum
sampl
collect
highrisk
group
includ
slaughterhous
worker
camel
handler
makkah
qassim
riyadh
provinc
sampl
includ
seroposit
sampl
seroneg
sampl
demonstr
mn
assay
sampl
anonym
studi
use
merscov
ab
test
base
ethic
approv
obtain
unit
biomed
ethic
king
abdulaziz
univers
hospit
microneutr
assay
perform
previous
describ
alamri
et
al
facil
special
infecti
agent
unit
siau
king
fahd
medic
research
center
king
abdulaziz
univers
briefli
heat
inactiv
serum
sampl
test
determin
highest
dilut
inhibit
cytopath
effect
cpe
tcid
vero
cell
viru
mix
equal
volum
serial
dilut
serum
sampl
start
dilut
plate
incub
confluent
vero
cell
monolay
plate
day
co
incub
serum
dilut
test
quadrupl
neutral
ab
titer
nab
determin
reciproc
highest
dilut
complet
prevent
cpe
well
mn
titer
consid
posit
posit
neg
control
alway
includ
recombin
merscov
spike
protein
includ
ectodomain
protein
amino
acid
subunit
amino
acid
tag
histidin
tag
purchas
sino
biolog
recombin
merscov
n
code
sequenc
access
number
isol
clone
prokaryot
express
plasmid
viral
rna
extract
code
cdna
pcr
amplifi
rtpcr
use
follow
forward
primer
cgc
ggc
cgc
gat
ggc
atc
ccc
tgc
tgc
acc
tcg
tgc
tg
revers
primer
cgg
tac
ctt
aat
cag
tgt
taa
cat
caa
tca
ttg
gac
c
introduc
noti
kpni
restrict
site
end
respect
amplifi
product
purifi
digest
ligat
vector
gener
recombin
protein
tag
nterminu
six
histidin
residu
clone
confirm
restrict
digest
sequenc
recombin
merscov
n
protein
express
purifi
e
coli
cell
use
nickelnitrilotriacet
acid
ninta
column
accord
manufactur
protocol
posit
fraction
pool
store
use
protein
confirm
western
blot
use
antihi
tag
ab
merscov
seroposit
seroneg
human
serum
sampl
immulon
hb
plate
thermo
scientif
rochest
ny
coat
merscov
rs
rn
protein
dilut
phosphat
buffer
salin
pb
overnight
plate
wash
pb
pbst
block
pbst
skim
milk
h
wash
plate
incub
serum
sampl
dilut
block
buffer
h
plate
wash
incub
peroxidaseconjug
sheep
antihuman
igg
amersham
ecl
pittsburgh
pa
dilut
h
wash
tetramethylbenzidin
tmb
substrat
kpl
gaithersburg
md
ad
well
incub
min
colorimetr
reaction
stop
tmb
bluestop
solut
kpl
gaithersburg
md
absorb
measur
spectrophotometr
nm
serum
sampl
test
duplic
sampl
optic
densiti
cutoff
valu
consid
posit
preliminari
cutoff
valu
elisa
assay
calcul
mean
neg
serum
od
valu
standard
deviat
sd
known
seroneg
serum
sampl
dilut
sensit
develop
elisa
calcul
number
true
posit
sampl
total
number
true
posit
fals
neg
sampl
specif
calcul
number
true
neg
sampl
total
number
true
neg
fals
posit
sampl
agreement
calcul
total
number
true
posit
neg
sampl
total
number
sampl
evalu
kappa
valu
receiv
oper
characterist
roc
analysi
calcul
use
graphpad
prism
softwar
roc
analysi
perform
determin
rel
sensit
specif
elisa
use
mn
result
refer
test
univari
analysi
use
spearman
correl
analysi
propos
elisa
mn
elisa
amongst
done
use
spss
imb
version
n
encod
gene
rtpcr
amplifi
merscov
genom
rna
clone
prokaryot
express
vector
histidin
tag
recombin
n
protein
induc
express
upon
induct
iptg
purifi
ninta
affin
chromatographi
column
shown
fig
merscov
rn
rs
protein
band
expect
size
respect
detect
antihi
tag
ab
western
blot
seroposit
serum
mer
patient
confirm
ident
protein
suggest
similar
antigen
nativ
protein
merscov
fig
expect
control
merscov
seroneg
serum
react
recombin
protein
fig
three
differ
elisa
develop
use
merscov
rn
rs
protein
coat
antigen
optim
work
concentr
antigen
serum
dilut
determin
use
checkerboard
titrat
highest
od
ratio
valu
posit
neg
sampl
pn
obtain
data
shown
concentr
coat
antigen
rang
optimum
concentr
found
rn
rs
similarli
serum
dilut
rang
appropri
serum
dilut
found
three
assay
use
serum
sampl
healthi
donor
serolog
neg
merscov
preliminari
cutoff
valu
mean
sd
found
mean
sd
rnelisa
mean
sd
mean
sd
rselisa
sampl
cutoff
rnelisa
fig
three
two
sampl
sampl
cutoff
valu
rselisa
fig
c
respect
od
valu
three
sampl
two
sampl
rselisa
total
human
serum
sampl
collect
highrisk
group
sampl
mn
titer
higher
sampl
neutral
activ
merscov
consid
serolog
neg
mn
assay
tabl
screen
sampl
develop
elisa
show
sampl
posit
three
elisa
predetermin
cutoff
valu
fig
without
fals
neg
sampl
give
sensit
three
elisa
hand
mnseroneg
cohort
individu
posit
test
rnelisa
rselisa
respect
result
show
highest
specif
good
agreement
kappa
mn
assay
follow
rselisa
show
specif
good
overal
agreement
kappa
mn
assay
lowest
specif
fair
agreement
kappa
mn
assay
observ
rnelisa
howev
preliminari
cutoff
valu
determin
use
sampl
lowrisk
group
may
reflect
actual
sensit
specif
assay
therefor
next
perform
roc
analysi
accur
determin
sensit
specif
cutoff
valu
develop
assay
use
sampl
control
highrisk
group
shown
fig
sensit
rselisa
remain
across
wide
rang
od
valu
selisa
compar
rnelisa
sensit
decreas
od
valu
reach
similarli
specif
rselisa
increas
od
valu
respect
comparison
rnelisa
show
specif
od
valu
exceed
result
suggest
better
cutoff
valu
rang
rselisa
respect
give
sensit
specif
lowest
number
fals
posit
neg
result
could
observ
intersect
sensit
specif
curv
thu
reliabl
cutoff
valu
could
result
sensit
specif
agreement
similarli
cutoff
valu
rselisa
could
result
sensit
specif
agreement
roc
analysi
show
low
accuraci
rnelisa
area
curv
auc
confid
interv
ci
hand
auc
rselisa
ci
ci
respect
suggest
rselisa
higher
accuraci
compar
rnelisa
fig
test
interassay
within
plate
intraassay
plate
variabl
show
minim
variat
obtain
od
valu
data
shown
suggest
high
reproduc
assay
univari
analysi
use
spearman
correl
show
high
signific
strong
correl
mn
titer
od
valu
selisa
r
p
r
p
respect
moder
strong
correl
mn
titer
rnelisa
r
p
furthermor
elisa
od
valu
strongli
correl
high
signific
direct
viru
detect
method
limit
need
proper
sampl
viru
shed
period
contrari
antimerscov
ab
detect
extend
period
time
thu
valid
serolog
assay
could
repres
valuabl
tool
diagnosi
well
epidemiolog
surveil
studi
furthermor
level
antimerscov
ab
shown
associ
diseas
sever
viral
load
suggest
could
util
prognost
marker
diseas
outcom
poissi
et
al
corman
et
al
choe
et
al
zhao
et
al
current
gold
standard
viru
neutral
assay
mn
prnt
altern
ppnt
assay
sensit
specif
excel
correl
howev
requir
skill
personnel
work
live
viru
high
contain
laboratori
avail
special
equip
continu
sourc
pseudovirus
case
ppnt
assay
assay
ifa
protein
microarray
expens
timeconsum
less
sensit
requir
train
technic
staff
special
equip
limit
render
assay
suitabl
largescal
highthroughput
screen
test
especi
merscov
endem
region
requir
limit
avail
therefor
aim
develop
compar
valid
differ
hous
elisa
base
merscov
n
recombin
protein
use
larg
number
well
character
human
sampl
provid
cheap
easi
tool
serolog
test
resourcelimit
region
data
show
three
develop
elisa
sensit
use
preliminari
cutoff
valu
specif
three
assay
nevertheless
roc
analysi
data
obtain
sampl
group
show
sensit
rs
elisa
maintain
across
wider
rang
od
valu
selisa
respect
compar
rnelisa
sensit
decreas
od
valu
also
specif
rs
elisa
reach
higher
od
valu
selisa
respect
give
bigger
dynam
rang
two
assay
rselisa
respect
compar
rnelisa
high
specif
result
huge
loss
sensit
addit
rs
elisa
show
higher
accuraci
better
correl
good
overal
agreement
mn
assay
comparison
rnelisa
data
suggest
follow
rselisa
sensit
specif
accur
rnelisa
benchmark
result
determin
mnassay
furthermor
shown
roc
analys
reliabl
cutoff
valu
rselisa
respect
could
use
epidemiolog
surveil
studi
cutoff
valu
indic
likelihood
specif
neutral
antibodi
titer
howev
valu
fall
preliminari
cutoff
determin
healthi
donor
one
determin
use
roc
analysi
consid
indetermin
valid
method
possibl
found
rnelisa
lower
sensit
compar
rs
elisa
line
previou
report
wang
et
al
recent
suggest
higher
sensit
compar
rselisa
across
wide
rang
od
valu
trivedi
et
al
discrep
could
explain
small
number
clinic
sampl
especi
highrisk
group
use
previou
studi
could
repres
limit
factor
actual
valid
assay
furthermor
n
protein
immunogen
abund
compar
glycoprotein
patient
might
delay
develop
anti
ab
chen
et
al
trivedi
et
al
common
antigen
epitop
across
differ
coronavirus
n
protein
could
lead
high
level
fals
posit
observ
rnelisa
agnihothram
et
al
chen
et
al
trivedi
et
al
hand
subunit
associ
less
crossreact
due
higher
divers
amongst
coronavirus
addit
genet
divers
merscov
clade
serolog
indistinguish
neutral
assay
detect
nab
target
epitop
within
subunit
hemida
et
al
muth
et
al
nonetheless
noteworthi
underscor
individu
highrisk
group
posit
elisa
result
three
develop
assay
without
detect
nab
mn
assay
could
expos
merscov
mount
true
igg
respons
lack
nab
especi
accumul
bodi
evid
suggest
ab
respons
mild
asymptomat
mer
case
might
transient
alshukairi
et
al
drosten
et
al
furthermor
recent
shown
serolog
test
elisa
mn
assay
might
captur
expos
infect
individu
highrisk
individu
could
mount
virusspecif
cell
respons
rather
detect
ab
respons
alshukairi
et
al
alshukairi
et
al
note
fals
posit
sampl
detect
also
posit
rselisa
rnelisa
highli
suggest
could
true
seroposit
sampl
lack
neutral
activ
therefor
believ
futur
studi
need
evalu
elisa
assay
elisa
base
pool
antigen
comparison
method
virusspecif
cell
respons
ifa
neutral
assay
sever
assay
develop
mrescov
serolog
test
includ
gold
standard
neutral
assay
practic
field
clinic
applic
need
use
live
merscov
high
contain
facil
furthermor
sever
group
alreadi
report
develop
elisa
base
assay
merscov
primarili
use
assay
anim
model
develop
test
sampl
camel
livestock
current
report
develop
evalu
three
differ
elisabas
assay
merscov
serolog
test
use
larg
number
character
clinic
sampl
assay
found
variat
sensit
specif
accuraci
correl
mn
assay
follow
rselisa
perform
better
rnelisa
develop
elisa
especi
base
rs
could
use
independ
combin
rnelisa
largescal
highthroughput
serolog
epidemiolog
screen
requir
high
contain
laboratori
could
adapt
lab
especi
requir
reagent
commerci
avail
amhash
conceiv
design
studi
amhass
sih
obh
nsa
ana
eia
collect
provid
sampl
ssa
tla
la
perform
experi
amhash
rya
aam
analyz
data
amhash
draft
manuscript
amhash
mma
ana
aam
eia
revis
manuscript
author
review
approv
manuscript
none
